Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (6): 573-579.doi: 10.11958/20221405
• Cell and Molecular Biology • Previous Articles Next Articles
DU Wenfeng(), ZHOU Ling, LI Qi(
)
Received:
2022-09-02
Revised:
2022-10-21
Published:
2023-06-15
Online:
2023-06-20
Contact:
△E-mail:DU Wenfeng, ZHOU Ling, LI Qi. Effects of CircCDR1as on the biological behavior of NSCLC cells by regulating the miR-671-5p/CBX4 axis[J]. Tianjin Medical Journal, 2023, 51(6): 573-579.
CLC Number:
细胞系 | CircCDR1as | miR-671-5p | CBX4 mRNA | CBX4蛋白 |
---|---|---|---|---|
HBE | 1.00±0.01 | 1.00±0.02 | 1.00±0.02 | 1.00±0.03 |
NCI-H524 | 3.92±0.14a | 0.59±0.05a | 2.86±0.14a | 2.54±0.11a |
NCI-H1734 | 4.09±0.21a | 0.52±0.06a | 2.95±0.18a | 2.63±0.14a |
Calu-3 | 4.15±0.19a | 0.41±0.04a | 3.18±0.23a | 2.75±0.21a |
A549 | 4.29±0.28a | 0.32±0.02a | 3.32±0.25a | 2.89±0.16a |
F | 328.965** | 243.424** | 160.266** | 175.065** |
Tab.1 CircCDR1as, miR-671-5p and CBX4 levels in HBE cells and NSCLC cell lines
细胞系 | CircCDR1as | miR-671-5p | CBX4 mRNA | CBX4蛋白 |
---|---|---|---|---|
HBE | 1.00±0.01 | 1.00±0.02 | 1.00±0.02 | 1.00±0.03 |
NCI-H524 | 3.92±0.14a | 0.59±0.05a | 2.86±0.14a | 2.54±0.11a |
NCI-H1734 | 4.09±0.21a | 0.52±0.06a | 2.95±0.18a | 2.63±0.14a |
Calu-3 | 4.15±0.19a | 0.41±0.04a | 3.18±0.23a | 2.75±0.21a |
A549 | 4.29±0.28a | 0.32±0.02a | 3.32±0.25a | 2.89±0.16a |
F | 328.965** | 243.424** | 160.266** | 175.065** |
组别 | CircCDR1as | miR-671-5p | 细胞活力(OD490值) | 克隆形成数(个) | 凋亡率 (%) | 迁移细胞数(个) | 侵袭细胞数(个) |
---|---|---|---|---|---|---|---|
Control组 | 1.00±0.03 | 1.00±0.02 | 1.18±0.21 | 91.45±7.62 | 10.02±0.91 | 94.38±8.12 | 97.56±6.89 |
si-NC组 | 1.00±0.02 | 0.99±0.03 | 1.17±0.19 | 91.38±7.49 | 10.01±0.89 | 94.29±7.91 | 97.54±6.85 |
si-CircCDR1as组 | 0.38±0.03ab | 1.78±0.06ab | 0.49±0.07ab | 38.62±3.51ab | 33.45±2.62ab | 40.15±10.03ab | 41.32±8.74ab |
si-CircCDR1as+anti-miR-NC组 | 0.39±0.02 | 1.75±0.08 | 0.47±0.06 | 38.67±3.48 | 33.48±2.14 | 40.18±10.06 | 41.35±6.95 |
si-CircCDR1as+anti-miR-671-5p组 | 0.91±0.05cd | 1.26±0.05cd | 0.99±0.12cd | 80.59±6.72cd | 14.13±1.06cd | 79.84±9.21cd | 80.69±7.24cd |
F | 611.941** | 328.761** | 36.693** | 121.564** | 315.182** | 55.305** | 90.091** |
Tab.2 Comparison of NSCLC cell viability, number of clone formation, apoptosis rate, migration and number of invasive cells between the five groups
组别 | CircCDR1as | miR-671-5p | 细胞活力(OD490值) | 克隆形成数(个) | 凋亡率 (%) | 迁移细胞数(个) | 侵袭细胞数(个) |
---|---|---|---|---|---|---|---|
Control组 | 1.00±0.03 | 1.00±0.02 | 1.18±0.21 | 91.45±7.62 | 10.02±0.91 | 94.38±8.12 | 97.56±6.89 |
si-NC组 | 1.00±0.02 | 0.99±0.03 | 1.17±0.19 | 91.38±7.49 | 10.01±0.89 | 94.29±7.91 | 97.54±6.85 |
si-CircCDR1as组 | 0.38±0.03ab | 1.78±0.06ab | 0.49±0.07ab | 38.62±3.51ab | 33.45±2.62ab | 40.15±10.03ab | 41.32±8.74ab |
si-CircCDR1as+anti-miR-NC组 | 0.39±0.02 | 1.75±0.08 | 0.47±0.06 | 38.67±3.48 | 33.48±2.14 | 40.18±10.06 | 41.35±6.95 |
si-CircCDR1as+anti-miR-671-5p组 | 0.91±0.05cd | 1.26±0.05cd | 0.99±0.12cd | 80.59±6.72cd | 14.13±1.06cd | 79.84±9.21cd | 80.69±7.24cd |
F | 611.941** | 328.761** | 36.693** | 121.564** | 315.182** | 55.305** | 90.091** |
组别 | CBX4 mRNA | CBX4蛋白 |
---|---|---|
miR-NC组 | 1.00±0.01 | 1.00±0.03 |
miR-671-5p组 | 0.38±0.04a | 0.42±0.04a |
anti-miR-NC组 | 1.00±0.02 | 1.00±0.02 |
anti-miR-671-5p组 | 2.12±0.06b | 1.71±0.08b |
F | 2 212.351** | 719.376** |
Tab.3 Comparison of mRNA and protein levels of CBX4 in A549 cells between the four groups
组别 | CBX4 mRNA | CBX4蛋白 |
---|---|---|
miR-NC组 | 1.00±0.01 | 1.00±0.03 |
miR-671-5p组 | 0.38±0.04a | 0.42±0.04a |
anti-miR-NC组 | 1.00±0.02 | 1.00±0.02 |
anti-miR-671-5p组 | 2.12±0.06b | 1.71±0.08b |
F | 2 212.351** | 719.376** |
组别 | CBX4 mRNA | CBX4蛋白 | 细胞活力(OD值) | 克隆细胞数 | 凋亡率(%) | 迁移细胞数 | 侵袭细胞数 |
---|---|---|---|---|---|---|---|
Control组 | 1.00±0.02 | 1.00±0.03 | 1.09±0.15 | 97.68±5.49 | 8.24±0.13 | 86.34±3.52 | 78.69±2.63 |
miR-NC组 | 0.99±0.03 | 1.01±0.05 | 1.07±0.13 | 97.75±5.63 | 8.26±0.15 | 86.38±3.61 | 78.72±2.62 |
miR-671-5p组 | 0.36±0.03ab | 0.33±0.02ab | 0.46±0.05ab | 39.54±2.16ab | 34.52±2.31ab | 40.15±2.03ab | 35.42±1.89ab |
miR-671-5p+pcDNA组 | 0.37±0.02 | 0.32±0.04 | 0.48±0.06 | 39.57±2.13 | 34.39±2.46 | 40.19±2.05 | 35.51±1.92 |
miR-671-5p+CBX4组 | 0.84±0.05cd | 0.81±0.05cd | 1.03±0.11cd | 82.36±4.25cd | 13.64±1.02cd | 81.23±3.12cd | 67.49±2.01cd |
F | 613.941** | 455.051** | 55.276** | 297.408** | 441.727** | 412.551** | 585.024** |
Tab.4 Comparison of NSCLC cell viability, number of clone formation, apoptosis rate, migration and number of invasive cells between the five groups
组别 | CBX4 mRNA | CBX4蛋白 | 细胞活力(OD值) | 克隆细胞数 | 凋亡率(%) | 迁移细胞数 | 侵袭细胞数 |
---|---|---|---|---|---|---|---|
Control组 | 1.00±0.02 | 1.00±0.03 | 1.09±0.15 | 97.68±5.49 | 8.24±0.13 | 86.34±3.52 | 78.69±2.63 |
miR-NC组 | 0.99±0.03 | 1.01±0.05 | 1.07±0.13 | 97.75±5.63 | 8.26±0.15 | 86.38±3.61 | 78.72±2.62 |
miR-671-5p组 | 0.36±0.03ab | 0.33±0.02ab | 0.46±0.05ab | 39.54±2.16ab | 34.52±2.31ab | 40.15±2.03ab | 35.42±1.89ab |
miR-671-5p+pcDNA组 | 0.37±0.02 | 0.32±0.04 | 0.48±0.06 | 39.57±2.13 | 34.39±2.46 | 40.19±2.05 | 35.51±1.92 |
miR-671-5p+CBX4组 | 0.84±0.05cd | 0.81±0.05cd | 1.03±0.11cd | 82.36±4.25cd | 13.64±1.02cd | 81.23±3.12cd | 67.49±2.01cd |
F | 613.941** | 455.051** | 55.276** | 297.408** | 441.727** | 412.551** | 585.024** |
组别 | CBX4 mRNA | CBX4蛋白 |
---|---|---|
Control组 | 1.00±0.03 | 1.00±0.02 |
si-NC组 | 1.02±0.05 | 1.01±0.03 |
si-CircCDR1as组 | 0.43±0.03ab | 0.49±0.05ab |
si-CircCDR1as+anti-miR-NC组 | 0.41±0.02 | 0.50±0.07 |
si-CircCDR1as+anti-miR-671-5p组 | 0.82±0.06cd | 0.87±0.09cd |
F | 322.880** | 121.304** |
Tab.5 Comparison of CBX4 expression in NSCLC cells between the five groups
组别 | CBX4 mRNA | CBX4蛋白 |
---|---|---|
Control组 | 1.00±0.03 | 1.00±0.02 |
si-NC组 | 1.02±0.05 | 1.01±0.03 |
si-CircCDR1as组 | 0.43±0.03ab | 0.49±0.05ab |
si-CircCDR1as+anti-miR-NC组 | 0.41±0.02 | 0.50±0.07 |
si-CircCDR1as+anti-miR-671-5p组 | 0.82±0.06cd | 0.87±0.09cd |
F | 322.880** | 121.304** |
[1] | HIRSCH F R, SCAGLIOTTI G V, MULSHINE J L, et al. Lung cancer:current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066):299-311. doi:10.1016/S0140-6736(16)30958-8. |
[2] | HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689):446-454. doi:10.1038/nature25183. |
[3] | BALATA H, FONG K M, HENDRIKS L E, et al. Prevention and early detection for NSCLC:Advances in thoracic oncology 2018[J]. J Thorac Oncol, 2019, 14(9):1513-1527. doi:10.1016/j.jtho.2019.06.011. |
[4] | TAN S, GOU Q, PU W, et al. Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer[J]. Cell Res, 2018, 28(6):693-695. doi:10.1038/s41422-018-0033-7. |
[5] | 安翠红, 宁文君, 马彩虹. 血清鳞状细胞癌相关抗原检测在超早期肺癌诊断中的应用价值[J]. 实用癌症杂志, 2019, 34(4):600-602. |
AN C H, NING W J, MA C H. Diagnostic value of serum squamous cell carcinoma associated antigen in the diagnosis of ultra early lung cancer[J]. Journal of Practical Cancer, 2019, 34(4):600-602. doi:10.3969/j.issn.1001-5930.2019.04.023. | |
[6] | BRAICU C, ZIMTA A A, HARANGUS A, et al. The function of non-coding RNAs in lung cancer tumorigenesis[J]. Cancers(Basel), 2019, 11(5):605-623. doi:10.3390/cancers11050605. |
[7] | WEI H, LI L, ZHANG H, et al. Circ-FOXM1 knockdown suppresses non-small cell lung cancer development by regulating the miR-149-5p/ATG5 axis[J]. Cell Cycle, 2021, 20(2):166-178. doi:10.1080/15384101.2020.1867780. |
[8] | NIU Y, HE J H, ZHANG Y, et al. Effect of the CircCDR1as/miR-641/XIAP regulatory axis on the proliferation and invasion of the prostate cancer PC-3 cell line[J]. Oncol Lett, 2021, 21(6):469-479. doi:10.3892/ol.2021.12730. |
[9] | XIONG X, FENG J, YANG X, et al. Circular RNA CDR1as promotes tumor progression by regulating miR-432-5p/E2F3 axis in pancreatic cancer[J]. Cancer Cell Int, 2021, 21(1):112-122. doi:10.1186/s12935-021-01812-3. |
[10] | LI P, YANG X, YUAN W, et al. CircRNA-Cdr1as exerts anti-oncogenic functions in bladder cancer by sponging microRNA-135a[J]. Cell Physiol Biochem, 2018, 46(4):1606-1616. doi:10.1159/000489208. |
[11] | CHEN H, MAO M, JIANG J, et al. Circular RNA CDR1as acts as a sponge of miR-135b-5p to suppress ovarian cancer progression[J]. Onco Targets Ther, 2019, 12(1):3869-3879. doi:10.2147/OTT.S207938. |
[12] | ZHANG X, YANG D, WEI Y. Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer[J]. Onco Targets Ther, 2018, 11(1):3979-3987. doi:10.2147/OTT.S158316. |
[13] | YE J, LUO W, LUO L, et al. MicroRNA-671-5p inhibits cell proliferation, migration and invasion in non-small cell lung cancer by targeting MFAP3L[J]. Mol Med Rep, 2022, 25(1):30-38. doi:10.3892/mmr.2021.12546. |
[14] | ZHAO X, WU X. Polycomb-group proteins in the initiation and progression of cancer[J]. J Genet Genomics, 2021, 48(6):433-443. doi:10.1016/j.jgg.2021.03.013. |
[15] | HU C, ZHANG Q, TANG Q, et al. CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer[J]. J Cell Mol Med, 2020, 24(1):618-631. doi:10.1111/jcmm.14771. |
[16] | 李莹, 孙万仆, 安志强, 等. 微小RNA-671-5p对人结肠癌细胞增殖、迁移和侵袭的影响[J]. 安徽医药, 2020, 24(5):942-946. |
LI Y, SUN W P, AN Z Q, et al. miR-671-5p inhibits colon cancer cell proliferation,migration and invasion by targeting CBX4[J]. Anhui Med Pharm J, 2020, 24(5):942-946. doi:10.3969/j.issn.1009-6469.2020.05.024. | |
[17] | ZHANG M, XIN Y. Circular RNAs:A new frontier for cancer diagnosis and therapy[J]. J Hematol Oncol, 2018, 11(1):21-30. doi:10.1186/s13045-018-0569-5. |
[18] | ALTORKI N K, MARKOWITZ G J, GAO D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis[J]. Nat Rev Cancer, 2019, 19(1):9-31. doi:10.1038/s41568-018-0081-9. |
[19] | LI Y, ZHANG J, PAN S, et al. CircRNA CDR1as knockdown inhibits progression of non-small-cell lung cancer by regulating miR-219a-5p/SOX5 axis[J]. Thorac Cancer, 2020, 11(3):537-548. doi:10.1111/1759-7714.13274. |
[20] | LEGRAS A, PÉCUCHET N, IMBEAUD S, et al. Epithelial-to-mesenchymal transition and microRNAs in lung cancer[J]. Cancers (Basel), 2017, 9(8):101-130. doi:10.3390/cancers9080101. |
[21] | DONG Y, HE D, PENG Z, et al. Circular RNAs in cancer: an emerging key player[J]. J Hematol Oncol, 2017, 10(1):2-10. doi:10.1186/s13045-016-0370-2. |
[22] | YANG W, YANG X, WANG X, et al. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ[J]. J Cell Mol Med, 2019, 23(8):4921-4932. doi:10.1111/jcmm.14305. |
[23] | GAO L, DOU Z C, REN W H, et al. CircCDR1as upregulates autophagy under hypoxia to promote tumor cell survival via AKT/ERK1/2/mTOR signaling pathways in oral squamous cell carcinomas[J]. Cell Death Dis, 2019, 10(10):745-761. doi:10.1038/s41419-019-1971-9. |
[24] | 许英杰, 张艳炜, 李海洲, 等. miR-671-5p对非小细胞肺癌细胞增殖和迁移及侵袭影响及其作用机制[J]. 中华肿瘤防治杂志, 2021, 28(20):1541-1548. |
XU Y J, ZHANG Y W, LI H Z, et al. Effects and mechanism of miR-671-5p on proliferation,migration and invasion of non-small cell lung cancer cells[J]. Chin J Cancer Prev Treat, 2021, 28(20):1541-1548. doi:10.16073/j.cnki.cjcpt.2021.20.05. | |
[25] | MA C, NIE Z K, GUO H M, et al. miR-671-5p plays a promising role in restraining osteosarcoma cell characteristics through targeting TUFT1[J]. J Biochem Mol Toxicol, 2020, 34(7):e22490-e22498. doi:10.1002/jbt.22490. |
[26] | ZENG J S, ZHANG Z D, PEI L, et al. CBX4 exhibits oncogenic activities in breast cancer via Notch1 signaling[J]. Int J Biochem Cell Biol, 2018, 95(1):1-8. doi:10.1016/j.biocel.2017.12.006. |
[27] | WEN L J, WANG Y S, TAN P Y. miR-515-5p inhibits the proliferation,migration and invasion of human breast cancer cells by targeting CBX4[J]. Exp Ther Med, 2021, 22(5):1328-1337. doi:10.3892/etm.2021.10763. |
[28] | PAN Y, LI Q, CAO Z, et al. The SUMO E3 ligase CBX4 is identified as a poor prognostic marker of gastric cancer through multipronged OMIC analyses[J]. Genes Dis, 2020, 8(6):827-837. doi:10.1016/j.gendis.2020.08.010. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||